Rho-kinase, a potential therapeutic target for the treatment of hypertension

Yoshitaka Hirooka, Hiroaki Shimokawa, Akira Takeshita

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Hypertension is a cardiovascular disorder characterized by increased peripheral vascular resistance and/or vascular structural remodeling. Recently, rapidly growing evidence from hypertensive animal models suggests that small GTPase Rho and its downstream effector, Rho-kinase, play an important role in the pathogenesis of hypertension. Activation of the Rho/Rho-kinase pathway is essential for smooth muscle contractility in hypertension. A greater RhoA expression and an enhanced RhoA activity have been observed in aortas of hypertensive rats, such as genetic spontaneously hypertensive rats and N ω-nitro-L-arginine methyl ester-induced hypertension. The enhanced RhoA expression and activity was already observed in young spontaneously hypertensive rats before the onset of hypertension. These results suggest that both genetic factors and blood pressure can upregulate RhoA expression. Moreover, Y-27632 or fasudil, the specific Rho-kinase inhibitors, markedly decreased blood pressure in various hypertensive model rats, but did not in normotensive animals. In addition, Rho-kinase inhibitors have been shown to inhibit hypertensive vascular lesion formation. Therefore, Rho-kinase inhibitors may have a therapeutic potential for the treatment of hypertensive patients.

Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalDrug News and Perspectives
Volume17
Issue number8
DOIs
Publication statusPublished - Oct 2004

Fingerprint

rho-Associated Kinases
Hypertension
Inbred SHR Rats
Vascular Resistance
Blood Pressure
Therapeutics
Monomeric GTP-Binding Proteins
Smooth Muscle
Blood Vessels
Aorta
Up-Regulation
Animal Models

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Rho-kinase, a potential therapeutic target for the treatment of hypertension. / Hirooka, Yoshitaka; Shimokawa, Hiroaki; Takeshita, Akira.

In: Drug News and Perspectives, Vol. 17, No. 8, 10.2004, p. 523-527.

Research output: Contribution to journalReview article

Hirooka, Yoshitaka ; Shimokawa, Hiroaki ; Takeshita, Akira. / Rho-kinase, a potential therapeutic target for the treatment of hypertension. In: Drug News and Perspectives. 2004 ; Vol. 17, No. 8. pp. 523-527.
@article{83a085fce5b14c3d8400d8142953cdfc,
title = "Rho-kinase, a potential therapeutic target for the treatment of hypertension",
abstract = "Hypertension is a cardiovascular disorder characterized by increased peripheral vascular resistance and/or vascular structural remodeling. Recently, rapidly growing evidence from hypertensive animal models suggests that small GTPase Rho and its downstream effector, Rho-kinase, play an important role in the pathogenesis of hypertension. Activation of the Rho/Rho-kinase pathway is essential for smooth muscle contractility in hypertension. A greater RhoA expression and an enhanced RhoA activity have been observed in aortas of hypertensive rats, such as genetic spontaneously hypertensive rats and N ω-nitro-L-arginine methyl ester-induced hypertension. The enhanced RhoA expression and activity was already observed in young spontaneously hypertensive rats before the onset of hypertension. These results suggest that both genetic factors and blood pressure can upregulate RhoA expression. Moreover, Y-27632 or fasudil, the specific Rho-kinase inhibitors, markedly decreased blood pressure in various hypertensive model rats, but did not in normotensive animals. In addition, Rho-kinase inhibitors have been shown to inhibit hypertensive vascular lesion formation. Therefore, Rho-kinase inhibitors may have a therapeutic potential for the treatment of hypertensive patients.",
author = "Yoshitaka Hirooka and Hiroaki Shimokawa and Akira Takeshita",
year = "2004",
month = "10",
doi = "10.1358/dnp.2004.17.8.863696",
language = "English",
volume = "17",
pages = "523--527",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Rho-kinase, a potential therapeutic target for the treatment of hypertension

AU - Hirooka, Yoshitaka

AU - Shimokawa, Hiroaki

AU - Takeshita, Akira

PY - 2004/10

Y1 - 2004/10

N2 - Hypertension is a cardiovascular disorder characterized by increased peripheral vascular resistance and/or vascular structural remodeling. Recently, rapidly growing evidence from hypertensive animal models suggests that small GTPase Rho and its downstream effector, Rho-kinase, play an important role in the pathogenesis of hypertension. Activation of the Rho/Rho-kinase pathway is essential for smooth muscle contractility in hypertension. A greater RhoA expression and an enhanced RhoA activity have been observed in aortas of hypertensive rats, such as genetic spontaneously hypertensive rats and N ω-nitro-L-arginine methyl ester-induced hypertension. The enhanced RhoA expression and activity was already observed in young spontaneously hypertensive rats before the onset of hypertension. These results suggest that both genetic factors and blood pressure can upregulate RhoA expression. Moreover, Y-27632 or fasudil, the specific Rho-kinase inhibitors, markedly decreased blood pressure in various hypertensive model rats, but did not in normotensive animals. In addition, Rho-kinase inhibitors have been shown to inhibit hypertensive vascular lesion formation. Therefore, Rho-kinase inhibitors may have a therapeutic potential for the treatment of hypertensive patients.

AB - Hypertension is a cardiovascular disorder characterized by increased peripheral vascular resistance and/or vascular structural remodeling. Recently, rapidly growing evidence from hypertensive animal models suggests that small GTPase Rho and its downstream effector, Rho-kinase, play an important role in the pathogenesis of hypertension. Activation of the Rho/Rho-kinase pathway is essential for smooth muscle contractility in hypertension. A greater RhoA expression and an enhanced RhoA activity have been observed in aortas of hypertensive rats, such as genetic spontaneously hypertensive rats and N ω-nitro-L-arginine methyl ester-induced hypertension. The enhanced RhoA expression and activity was already observed in young spontaneously hypertensive rats before the onset of hypertension. These results suggest that both genetic factors and blood pressure can upregulate RhoA expression. Moreover, Y-27632 or fasudil, the specific Rho-kinase inhibitors, markedly decreased blood pressure in various hypertensive model rats, but did not in normotensive animals. In addition, Rho-kinase inhibitors have been shown to inhibit hypertensive vascular lesion formation. Therefore, Rho-kinase inhibitors may have a therapeutic potential for the treatment of hypertensive patients.

UR - http://www.scopus.com/inward/record.url?scp=10444246505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444246505&partnerID=8YFLogxK

U2 - 10.1358/dnp.2004.17.8.863696

DO - 10.1358/dnp.2004.17.8.863696

M3 - Review article

VL - 17

SP - 523

EP - 527

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 8

ER -